Pfizer can't derail Celebrex suit; New edict from India; Teva, Lonza rethink biosimilars pact;

 @FiercePharma: Reports of serious reactions to Affymax's Omontys surfaced last August, WSJ says, 6 months b/f recall. More | Follow @FiercePharma

 @EricPFierce: Pfizer's Xeljanzi forecast to hit $1.86 billion by 2016 but Amarin's Vascepa disappoints. Story | Follow @EricPFierce

> Lonza and Teva Pharmaceutical Industries ($TEVA), which suspended their work in October on a biosimilar of Roche's ($RHHBY) drug MabThera, are evaluating whether to proceed with their biosimilar joint venture. Story

> Pfizer ($PFE) was unable to derail a shareholder lawsuit that claims execs made misleading statements about the safety of sales potential of arthritis drugs Celebrex and Bextra. Story

> Teva has gotten FDA approval for Quartette, a new birth control drug developed to minimize breakthrough bleeding between periods. Item

> Canada's Apotex, already in a NAFTA fight with U.S. over a 2009 FDA import ban, has found itself back in the agency's doghouse. Story

> Ranbaxy Laboratories has restored supplies of generic Lipitor in the U.S. Report

Medical Device News

 @FierceMedDev: Dx approach offers chance to spot pancreatic cancer earlier. Story | Follow @FierceMedDev

 @MarkHFierce: Sony and Olympus have delayed their joint medical device venture again. Talk about unrealized potential. More | Follow @MarkHFierce

 @DamianFierce: A Chinese court is asking the SFDA to crack down on local clinical trial regulations. Article | Follow @DamianFierce

> ResMed battles Taiwanese outfit in apnea device patent fight. Item

> Olympus, Sony postpone joint medical device venture indefinitely. Article

> Covidien defeats J&J/Ethicon in surgical tool patent battle. News

Biotech News

 @FierceBiotech: Sanofi to build $75m plant in Vietnam. Market there growing fast, and so is payer coverage. Article | Follow @FierceBiotech

 @JohnCFierce: While India's SC strikes at pharma, the U.K. tees up a sweet tax deal for patented pharma products--the "patent box." More | Follow @JohnCFierce

 @RyanMFierce: Amgen claimed Big Data software prize in $415M deCODE buyout. Report | Follow @RyanMFierce

> New math on biosimilars sends a chilling message to Lonza/Teva team. More

> Clashing stands of India, U.K. on drug patents, R&D will offer clear lessons. Article

> J&J wins first FDA approval for new class of diabetes drug. News

CRO News

> Biotrial takes tech, talent from failing Forenap. Story

> ReSearch launches joint venture with Japanese CRO. News

> bioRASI buys Ukraine CRO for E. Europe heft. Article

> Frontage gets FDA chiding over Chinese lab. Item

> Chinese court wants tougher clinical trial regs. Report

Biotech IT News

> George Church-affiliated startup blueprints genetic data marketplace. News

> FoldIt creator wins Bill Gates nod for science crowdfunding site. Item

> Sequoia-backed genomics startup, others face who-pays hurdle. Story

> NSF touts role of supercomputer in autism, neuroscience discoveries. Article

> Big Data sheds light on pharma's 'Small Data' problems. Industry Voices

> 5 keys to going mobile in pharma. Editor's Corner

And Finally... India, which has significantly increased the number of drugs covered by price controls, says manufacturers must give a 6-month notice if they are discontinuing a product and that the government can force them to continue production to meet essential needs. Report

Suggested Articles

With generics at the gates, Novartis’ Gilenya secured a breath of fresh air—and protection for its blockbuster sales—with a federal injunction.

Akorn has been slammed with another FDA warning letter even as it is in the process of renegotiating its loans with lenders.

Horizon Therapeutics is preparing for the potential launch of inflammatory eye drug teprotumumab with team building.